image credit: Unsplash

FDA advisers back maternal use of Pfizer RSV vaccine

May 19, 2023

The vaccine, if approved, would be the first available for protecting infants from a pathogen that each year kills hundreds of young children. It is one of a recent wave of drugmaker successes against the disease after decades of effort. The U.S. approved the first vaccine for RSV for use in older adults earlier this month and could soon approve a long-acting antibody for RSV in babies that Europe cleared in November.

Read More on Biopharma Dive